EVENT January 7, 2013

OneMedForum SF 2013

Jan 7-9th 2013 Following the New Year the Immune Team will be presenting at the OneMedForum in San Francisco.

Keep Reading

NEWS December 6, 2012

BioTuesday: “Immune-EpiCept to get multiple clinical shots on goal”

December 6, 2012 The Immune-Epicept merger was featured on BioTuesdays.com, a weekly highlight of Global Healthcare. The feature covers that the proposed union of closely held Immune Pharmaceuticals of Israel and EpiCept (NASDAQ OMX Stockholm, OTCQX: EPCT) will create a combined company focused on antibody therapeutics for cancer and inflammation, with four products in the […]

Keep Reading

PRESS RELEASE November 14, 2012

EpiCept Reports Third Quarter 2012 Operating and Financial Results

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News : EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) (the Company) today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million. These compare with net losses for the […]

Keep Reading

PRESS RELEASE November 12, 2012

EpiCept to Report Third Quarter 2012 Operating and Financial Results on November 14, 2012

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News : EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that it will host a conference call on Wednesday, November 14, 2012 at 9:00 a.m. Eastern time to discuss recent events and the third quarter 2012 operating and financial results. The call will follow the release of these […]

Keep Reading

EVENT November 12, 2012

Bio-Europe 2012

Nov 12-14: The Immune Team will be participating in the Bio-Europe Conference in Hamburg.

Keep Reading

November 8, 2012

Immune-Epicept Merger

Nov 8, 2012 Immune Pharmaceuticals Ltd. and EpiCept Corporation (EPCT) announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013. The combined company will be focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.2

Keep Reading

PRESS RELEASE November 8, 2012

Immune Pharmaceuticals and EpiCept Corporation Agree to Merge

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y. –(BUSINESS WIRE)– Regulatory News : Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (“EpiCept”) (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT) today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is […]

Keep Reading

EVENT November 5, 2012

NEIBC Life Sciences Summit

Nov 5-6, 2012: The Immune Team is presenting at the New England-Israel Business Council’s Life Sciences Summit in Boston.

Keep Reading